Navicixizumab (Anti-DLL4 & VEGF)

製品コード：A4056        

印刷

Navicixizumab is a bispecific monoclonal antibody targeting DLL4 and VEGF, with potential anti-angiogenic and antineoplastic activities. It has shown antitumor effects in multiple cancer types, with the most promising results in ovarian cancer. M.W 146.17 kDa

製品説明

CAS No. 1638338-43-8
Source CHO
Storage
(From the date of receipt)		 -80℃(avoid freeze-thaw cycles)
Shipping Shipped under low temperature conditions

人間や獣医の診断であるか治療的な使用のためにでない。